Posted by Michael Wonder on 19 Sep 2020
Agenus initiates rolling BLA submission of balstilimab for recurrent/metastatic cervical cancer
18 September 2020 - Agenus announced the initiation of the rolling submission of its biologics license application to the U.S. FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.
Balstilimab is a novel anti-PD-1 human monoclonal antibody that has demonstrated promising clinical benefit in second line treatment of cervical cancer.
